Frontiers in Health Informatics
ISSN-Online: 2676-7104
www.healthinformaticsjournal.com
2024; Vol 13: Issue 5
Open Access

Synergistic Effect Of Administration Of Nutraceuticals In Polycystic Ovarian Syndrome In Tertiary Care Hospital

Dr. Suresh Chandra Mondal[1],*, Dr. Soham Chowdhury[2], Dr. Brotin Mukherjee[3], Dr. Uttara Nandi[4]

[1.] Associate Professor, Department of Obstetrics and Gynecology , Malda Medical College & Hospital, Malda, West Bengal, India

[2.] Assistant professor, MS(G&O), MBBS(HONS), G&O, Malda Medical College & Hospital, Malda, West Bengal, India

[3.] Dr. Brotin Mukherjee, MS(G&O), (2nd Year PGT), Malda Medical College & Hospital, Malda, West Bengal, India

[4.] Dr. Uttara Nandi, MS(G&O), (2nd Year PGT), Malda Medical College & Hospital, Malda, West Bengal, India

Cite this paper as: Dr. Suresh Chandra Mondal, Dr. Soham Chowdhury, Dr. Brotin Mukherjee, Dr. Uttara Nandi (2024) Synergistic Effect Of Administration Of Nutraceuticals In Polycystic Ovarian Syndrome In Tertiary Care Hospital. *Frontiers in Health Informatics, 13* (5), 250-269

Abstract

Polycystic Ovary Syndrome (PCOS) is an endocrine disorder in women of childbearing age, present in approximately one-third of women in the reproductive age group. Hormonal disorders, metabolic complications, and ovulatory disorders manifest themselves. Because conventional treatments may have side effects and their efficacy ranges from good to poor, there is a growing interest in nutraceuticals as additional therapy. The rationale for this study is to assess the clinical combined interaction of some chosen nutraceuticals which have been reported to work on hormonal balance and metabolism of women with PCOS, such as myoinositol, D chiro inositols, omega three fatty acids, and vitamins and minerals.

Female subjects aged 18-40 years presenting to the outpatient clinic with Rotterdam criteria defining PCOS will be recruited prospectively in this trial. After six months, participants will have been randomized to either receive the blend of nutraceuticals or a placebo. Fertility (ovulation rates and fertility status) and metabolic (fetal growth and insulin sensitivity) outcomes will be positively correlated with hormonal (testosterone, LH, and FSH) outcomes, which will help elucidate the role of testosterone signalling in each outcome.

The nutraceutical interventions are anticipated to demonstrate highly significant changes in all hormonal parameters and general metabolic conditions of the intervention group compared to the control group. More particularly, testosterone levels are expected to decline, insulin sensitivity to improve, and ovulation rates to increase. Such findings also establish the possibility of using nutraceuticals to enhance the outcomes of conventional approaches to managing PCOS adequately.

Keywords: Polycystic Ovary Syndrome, Nutraceuticals, Myo-inositol, D-chiro-inositol, Hormonal Balance, Fertility Outcomes

1. Introduction

Polycystic ovary syndrome (PCOS) is an endocrine disorder affecting women mainly restricted to the reproductive age range, with an estimated global prevalence of 5 % − 18 % (Abbasi, 2019; Kiani et al., 2022). PCOS is a condition characterized by a combination of symptoms: abnormal menstrual cycles, excess male hormones, and polycystic ovaries, which have severe consequences for women's health, including infertility, metabolic disorders, and cardiovascular diseases (Aversa et al., 2020). Due to understanding PCOS from almost all aspects, it is gradually being accepted as a condition. Consequently, knowledge of its pathophysiology, as well as treatment, is crucial to success.

PCOS has many clinical symptoms that can affect the quality of life of afflicted humans. These shared symptoms also cause psychological distress and reduced self-esteem, which has been indicated by authors such as Gavali et al. (2021). Also, features of PCOS include insulin resistance and obesity, which exacerbate the disease and associated risk of type 2 diabetes mellitus and cardiovascular diseases (Zhao et al., 2019; Ajibare, A., et al., 2023). These implications show that there is a substantial demand for practical solutions to fill the hormonal and metabolical gap of PCOS.

Due to the growing demand for nutraceuticals in the past years, these have become a potential supplement to the conventional management of PCOS. Nutraceuticals are particular food items that are intended to have a health-promoting and disease-preventing effect apart from their primary function of providing nutrition; the category of products is composed of a wide array of bioactive molecules that might be beneficial to correct impaired hormonal status, insulin resistance and inflammation (Asad, M., et.al., 2019; Chudzicka-Strugała, I., 2021; Chopra, K. 2018). For instance, omega-3 fatty acids, myo inositol, D chiro inositol and vitamin E, trace elements, calcium, magnesium, and selenium. These compounds have been studied to determine the possible decrease in the manifestation of PCOS without provoking side effects, which are familiar with pharmacological treatment (Alesi et al., 2022; Corrie, L., 2021; Genazzani et al., 2020).

The rationale for considering nutrient supplements in treating PCOS is connected with a current therapy's shortcomings. More traditional medications like metformin or hormonal contraceptives are used for symptom control but have severe side effects and are contraindicated for many patients (Akhtar et al., 2021). For instance, metformin causes gastrointestinal upsets and is ineffective in patients who are not overweight (El-Garhi et al., 2019). Besides, most females with PCOS are clinically discontented with the typical care and yearn for more natural ways of conceiving without using hormones (Kaur & Verma, 2023; Bizzarri, M., & Monti, N. (2019)). The study of the interactions of these nutraceuticals opens the door to enhancing treatment abilities because this is possible by the patient's choice.

The present study also seeks to evaluate the synergistic effect of various essential nutraceuticals in alleviating hormonal and metabolic aspects of women with PCOS syndrome. This study will interpret the efficacy of combined nutraceutical supplementation with systematic nutraceutical intervention, providing a randomized control trial based on the existing therapies. Furthermore, the expected benefits include enhanced insulin sensitivity, a higher degree of hyperandrogenism, an increased fertility rate, and overall fertility health. The conclusion of the present study could provide significant clues on how the use of nutraceuticals has the potential to enhance the clinical management of PCOS.

Literature Review

2.1 Overview of Current Treatments for PCOS

Polycystic Ovary Syndrome (PCOS) is a syndrome, an endocrine disorder with multiple symptoms: irregular menstrual cycle, hyperandrogenism, and polycystic ovaries. The present interventions are more acute, focusing on metabolic complications. The insulin sensitizer metformin has been broadly investigated in managing Type 2 DM, and its effectiveness is confirmed. Still, in patients with PCOS, metformin is incredibly efficient in enhancing insulin sensitivity due to a rising trend towards hyperinsulinemia characteristic of the disease, which is one of the pathological connections in the development of PCOS (Akhtar et al., 2021; González et al., 2020). Several clinical trials have shown that metformin enhances ovulation rates and corrects menstrual cycle irregularities in women with insulin resistance (Li et al., 2019). Furthermore, it implied that the drug is not side-effect-free because adverse effects common with the gastrointestinal system include nausea, vomiting, and diarrhoea (Zhao et al., 2019; Gulati, M., 2021). Furthermore, the effects of metformin may take years to persist, while cessation of metformin treatment leads to rapid glycemic deterioration.

Metformin is often given in combination with drugs used for the relief of other features, such as hirsutism or menstrual irregularities. COCs are established to manage menstrual cycles and reduce androgens that reduce acne and hirsutism (Kaur & Verma, 2023; Alesi et al., 2022). COCs do not correct the insulin resistance in PCOS and are also essentialized with thromboembolic occurrences. Clomiphene citrate medications are used in women who want to have children, although sometimes, their efficacy ranges in women (El-Garhi et al., 2019; Corte, L., 2020; Emam, S., et al., 2021).

While most conventional treatments are effective in controlling PCOS symptoms, they do so with significant side effects and fail to treat the problem entirely. It then gives us a reason why we need other or complementary therapies that would improve with holistic management and without undesirable side effects.

2.2 Nutraceuticals in PCOS Management

Recently, nutraceuticals as adjunctive therapies for PCOS have received increased interest. Nutraceuticals (food products with additional health benefits besides essential nutrition) may be crucial in managing PCOS. The type of nutraceuticals, including omega-3 fatty acids, have been found to assist in enhancing metabolic efficiency.

Table 1: Optimal Nutraceutical Combinations for PCOS Management

Nutraceutical Combination	**Dosage**	**Expected Outcomes**
Myo-inositol + D-chiro-inositol	Myo-inositol: 2000 mg/day D-chiro-inositol: 50 mg/day	Improved insulin sensitivity; reduced testosterone levels; and enhanced ovulation rates.
Myo-inositol + Melatonin + ALA	Myo-inositol: 2000 mg/day Melatonin: 2 mg/day ALA: 600 mg/day	Significant hormonal balance restoration; improved metabolic markers.

Thistable presents the optimal nutraceutical combinations to manage symptoms of PCOS. The addition of melatonin and alpha lipoic acid (ALA) to myo and D chiro increases the benefits of this addition significantly, and the addition of melatonin and ALA to myo and D chiro increases the benefits of this addition significantly. These findings support recent studies (El-Garhi et al., 2019; Zhu, X., & Fu, Y. 2019; Yang, H.,2022) and together with recent studies (Thakur, D., 2021; Shamasbi, S., et al., 2019), indicate that a multi-nutraceutical approach might be a complete strategy to address both metabolic and reproductive challenges in women with

PCOS.

2.2.1 Omega-3 Fatty Acids

Many investigations have looked into different ways that omega-3 fatty acids may be helpful for individuals living with PCOS. These fatty acid studies suggest that they could positively impact the metabolic points of insulin sensitivity and lipid balance (Zhou et al., 2022). Many randomized controlled trials added to a systematic review presented that omega-3 three notably decreased insulin resistance levels using the HOMA index (Yang, L., et al., 2023; Vitale, S., et al., 2020; Vaidya, A., et al., 2020). Overall, self-rated and combined study quality suggested that Omega-3 participants had a substantially lower insulin resistance of -0.80(-0.89 to - 0.71; $P < 0.00001$) compared to control groups.

Further, omega-3 has been known to produce positive changes in lipid profiles, including lowering total cholesterol and triglycerides (Shikh, E., et al., 2022). Specifically, omega-3 fatty acids supplementation statically affected total cholesterol by - 9.43 mg/dL, triglyceride - 29.21mg/dL, and high-density lipoprotein cholesterol by + 20.29 mg/dL. Such lipid-modulating effects are also helpful; more so, the risk of cardiovascular problems is higher in women with PCOS.

Omega-3 fatty acids can sometimes aid hearts and have anti-inflammatory properties for women with PCOS. This syndrome is defined by the presence of one of the following disorders: a low-grade inflammation coupled with other metabolic disorders, including insulin resistance (González et al., 2020). Based on the findings, omega-regard supplementation is said to decrease inflammatory cytokines, such as CRP, and, therefore, might assist in mitigating the effects of PCOS.

However, this much can be said – It is essential to ensure that everyone is aware that, like each other nutrient supplement, more research is being made to determine the optimal intake of omega-3 fatty acids and the time frame within which the nutrient should be consumed. Sen et al. (2023) studies have found positive effects, just at about 3g/day for 12 weeks or less, but the planned dose regimen for treatment now in clinical trials needs to be defined in further research.

2.2.2 Inositol Variants

However, sinceD-chiro-inositoland Myo-inositol have similar functions in the regulation of hormones and reproductive systems, respectively, both of them have been used as potent nutraceuticals for PCOS. Myo-inositol – a natural isomer of inositol– has proven to positively impact metabolic indices and insulin resistance for women with PCOS (Afiat et al., 2022; Romualdi, D., et al., 2020). This compound reduces insulin sensitivity, a characteristic of PCOS, and improves ovarian function and menstrual cycle (Davinelli et al., 2020; Sadeghi, H., et al., 2022).

The latter systematic review of RCTs suggests that Myo-inositol supplementation enhances ovulatory performance in women with PCOS as well as acts in the direction of an overall improvement of metabolic syndrome in the same population (Gonzalez et al., 2020; Raoofi, A., et al., 2022). One example: According to one analysis of the effects of Myo-inositol on women, ovulation levels were significantly higher than in women given a placebo in that particular research (Rocha, A., et al., 2019; Ragy, M., et al., 2018; Rezaei, M., et al., 2021). These investigations describe doses between 2000 and 6000 mg daily connected with the positive impact on hormonal balance and metabolism.

However, myo-inositol is a supplement to D-chiro-inositol. It has been suggested that the combination ofD-

chiro-inositoland Myo-inositol in a specific ratio can enhance the efficacy of the treatment in women with PCOS (Alesi et al., 2022; Genazzani et al., 2020). It is recognized that this ratio reflects the actual physical requirements of ovarian tissues. It is connected with the proportion between the concentration of D-chiro-inositoland Myo-inositol for the adequate functioning of the metabolism and the treatment of the irregular menstrual cycle and hyperandrogenism (Pierro, F., et al., 2023;Peng, F., et al., 2022). The modifications in the hormonal data demonstrated in this study are the following: There is a reduction in luteinizing hormone, a decrease in testosterone, and a reduction of the HOMA-IR index, which characterizes insulin resistance (Ibrahim et al., 2020). The participants received a supplementation of D-chiro-inositol for twelve weeks.

Co-administration of these two inositol may produce additive actions that will enhance reproductive efficiency compared to individual compounds. However, this combo has enhanced the oocyte quality and the response rates in the ARTs in case-control studies (Parker, M., et al., 2020; Ostadmohammadi, V., et al., 2019; Xu et al., 2022). Nevertheless, these agents' doses and treatment lengths must be studied further to provide scientific protocols for clinicians' daily practice.

2.2.3 Vitamins and Minerals

Vitamins and minerals are needed for hormonal control of PCOS and balance restoration. Ironically, vitamin D has elicited little interest because of its frequent consumption among women with PCOS and an apparent association with fertility health (Abhari et al., 2020; Nazirudeen, R., et al., 2022). For instance, the researchers identified that Vitamin D deficiency causes hysterectomy, abnormalities of the female reproductive cycle, infertility, and insulin resistance familiar with polycystic]ovary syndrome (PCOS) (Kaur & Verma, 2023). Some evidence suggests that Vitamin D supplements help manage the problem of Irregular menstrual periods and fertility outcomes.

Based on some works, it is stated that giving vitamin D to women with PCOS results in changes in the menstrual cycle and serum testosterone levels in these patients (Dastorani et al., 2019; Naseri, L., et al., 2021). However, Vitamin D is associated not only with reproduction, metabolism, weight, and PCOS. It also revealed that Vitamin D benefits insulin resistance and inflammation biomarkers, key treatment factors for the frequent metabolic syndrome among PCOS patients (Zhou et al., 2022; Espinoza, J., 2018).

Another mineral that may be useful in managing PCOS is zinc. For this condition, many women usually lack zinc, which increases hirsutism because zinc plays a critical role in androgen metabolism (Cocetta et al., 2022; Gadani, M., et al., 2023; Mondal, S., & Sarkar, P. (2021)). The literature review showed that zinc can reduce serum testosterone levels besides enhancing hyperandrogenism skin disorders (Ghanei et al., 2018; Menichini, D., et al., 2018).

2.3 Synergistic Effects of Nutraceutical Combinations

Multiple nutraceutical use is much more therapeutically effective than using single substances only. The previous research also indicates that individual nutrients have synergistic effects for clinical enhancement in women with PCOS when used in combination. For instance, for Myo-inositol, D-chiro-inositol, melatonin, ALA, vitamin E, and other compounds, results of quite different investigations indicate relatively favourable effects (Genazzani et al., 2020; Malvasi, A., et al., 2022; Gao, Z., et al., 2022; Alesi et al., 2022).

In one learn, the best package of myoinositol, melatonin, and ALA was established to cure hormonal PCOS in all women's age and BMI groups (Ranjbary et al., 2022; Cui, D., et al., 2022; Giri, A., et al., 2022). This was

stated to afford marked improvement against all the PCOS features examined over six months. In particular, the interaction minimized insulin resistance and enhanced ovarian capacity.

However, blending nutraceuticals can target multiple problems simultaneously and in the treatment plans. For instance, oral preparations of myoinositol combined with vitamin D improve insulin sensitivity and fertility as regular ovulation is stimulated (Leena, M., et al., 2021; Atwa, K., et al., 2020; Jamilian, M., et al., 2019). The idea that PCOS-affected women experience many symptoms makes this multipronged strategy all the more beneficial.

Methodology

3.1 Study Design

This will be a prospective, parallel-group, randomized control trial of the efficacy of different nutraceuticals in the management of signs/symptoms of PCOS. This research particularly applies to RCT design because it offers a comprehensive and orderly comparison of treatment effects while keeping biases to a minimum due to the random allocation of participants to the intervention groups. Inter- and interrater blinding will be employed where participants and the assessors cannot tell belonging to which group, thus reducing the placebo effect and observer bias. Such an approach makes validation of the results possible, hence providing sound conclusions about the effectiveness of the nutraceutical interventions.

During the six months, the participants will be given a nutraceutical combination and placebo. In addition to sleep apnea, factors causing variation in the hormonal levels (testosterone, LH, FSH), metabolic (insulin sensitivity, fasting glucose), and PCOS-associated disease symptoms (dyslipidemia) with PCOS as the primary outcomes will be evaluated. The study focuses on these outcomes to provide a complete perspective of nutraceuticals' effect on Hormonal balance and reproductive health.

3.2 Participant Recruitment

Of patients from the outpatient departments of the Malda Medical College and Hospital systematically, all women aged 18 to 40 years with diagnosed PCOS based on Rotterdam criteria will be included. Inclusion criteria will encompass women exhibiting at least two of the following characteristics: clinical and laboratory features of hyperandrogenism, including hirsutism or raised testosterone levels and ultrasound evidence of polycystic ovaries (Aversa et al., 2020; Bahman, A., et al., 2018).

Individuals with other hormonal disorders, severe cardiac disease, liver disease, major psychiatric illness, and those who are pregnant or are receiving hormonal medications will be excluded. This careful selection process is critical so that the study population is homogeneous and the 'causes' of observed effects are indeed the nutraceutical interventions.

In the process of recruitment, extra Participant Enrollment Strategies will be adopted. Such strategies will include word of mouth through health care providers, print media adverts on local newspapers and poles, and Facebook and Twitter campaigns for women with PCOS. However, research has shown that multiple strategies can boost participant enrolment and retention in clinical trials by a significant percentage (Kłosińska, M., & Kaczyńska, A... 2021; Kelany, O., et al., 2020; Scannell et al., 2023).

3.3 Intervention Groups

Participants will be arbitrarily assigned to one of two intervention groups: Group A will be subjected to a blend ofD-chiro-inositoland Myo-inositol in a 40:1 ratio and other vitamins and minerals, particularly Vitamin D and zinc. Group B will use only a placebo. The dosages for Group A will be as follows: interference of 2000 mg Myo-inositol, 50 mg D-chiro-inositol, 1000 IU Vitamin D daily, and 25 mg Zinc daily. Supplementation will take six months.This specific combination was chosen based on literature providing evidence that treatment with D-chiro-inositol in combination withMyo-inositol could synergistically improve insulin sensitivity and get better ovarian function (Davinelli et al., 2020; Kiani A., et al., 2022; Merviel et al., 2021; Khajouei, A., et al., 2021). Vitamins and minerals are included to compensate for deficiencies commonly seen in women with PCOS and maybe overall metabolic health for women with PCOS.

3.2 Participant Recruitment

Samples will consist of outpatient women aged between 18 – 40 years attending the outpatient department of Malda Medical College & Hospital diagnosed with PCOS according to Rotterdam criteria. Inclusion criteria encompass women exhibiting at least two of the following characteristics: clinical and biochemical hyperandrogenism as hirsutism or testosterone levels, oligoovulation/anovulation, or polycystic ovaries on ultrasound.

Comorbidities like other hormonal conditions, severe cardiovascular problems, liver problems, significant psychiatric problems, pregnancy, or who are currently on hormonal medications will be excluded. The careful selection process also guarantees that the study population is homogeneous and that the effects observed can be attributed to the nutraceutical interventions and not to other confounding factors.

Several strategies will be used to recruit participants. Healthcare providers will be referred, adverts will go out in local media, and social media campaigns will target women with PCOS. Previous work has shown that a diversity of recruitment methods can considerably improve participant engagement and retention in clinical trials (Scannell et al., 2023).

3.3 Intervention Groups

Participants will be randomly assigned to one of two intervention groups: Group A will take a ratio of D-chiro-inositol and Myo-inositol at 40:1 with other vitamins and minerals: Vitamin D and Zinc. They will take a placebo treatment in Group B. The dosages for Group A will be as follows: I administered 2000 mg of myo-inositol each day and 50mg of D-chiro-inositol, respectively, Vitamin D of 1000 IU a day, and 25mg of zinc per day. Supplementation shall be for half a year.

These nutrients are selected since simultaneously increasing their intake is essential for enhancing insulin sensitivity (Davinelli et al., 2020; Merviel et al., 2021). Fibre is added to the ingredients to address the lowered fibre intake commonly seen in women with PCOS, and vitamins and minerals added to the formula to help address deficiencies often seen in women with this condition may also have an impact on the metabolic health of women with PCOS.

3.4 Data Collection Methods

Standardized protocols will be used to collect data at baseline (baseline: pre-intervention) and after six months (post-intervention). Blood samples drawn following overnight fasting will test for hormones arriving from Luteinizing hormone, follicle-stimulating hormone, testosterone, estradiol, and insulin hormone. These

hormonal assessments include nutraceutical interventions for the evaluation of hormonal balance efficacy.
Secondary metabolic measurements, including BMI, waist circumference, fasting glucose, and lipid profile, will also be taken before and after the intervention. Insulin resistance will be determined by homeostasis model assessment- insulin resistance; sample data presented here are fasting insulin and glucose levels (González et al., 2020).
At both times, the subjects will complete validated questionnaires to assess clinical outcomes of PCOS symptoms, including but not limited to regularity of menstrual cycle, hirsutism (Ferriman Gallwey score), and quality of life. This comprehensive data collection approach is characteristic of a multiple perspective PCOS approach that amasses data across several PCOS categories for enhanced generalisability of treatment outcomes.

4. Expected Results

4.1 Hormonal Improvements

Nutraceutical interventions are expected to elicit significant hormonal changes, beginning with regulating androgens and ovulatory function. Other research papers have also shown ways through which taking of D-chiro inositoland Myo-inositol cause the reduction of serum testosterone levels, which helps to address symptoms such as hirsutism and acne in women suffering from PCOS (Afiat et al., 2022; Merviel et al., 2021). One of the studies is a randomized controlled trial wherein a woman taking Myo-inositol had her serum total testosterone reduced by 66 % and her free testosterone by 73 % compared to the placebo group (Ibrahim et al., 2020).
Furthermore, combiningD-chiro-inositoland Myo-inositol in a physiological relation of 40:According to Davinelli et al. (2020), the former significantly improves menstrual regularity and restores spontaneous ovulation. Consequences ranged from an increase in ovulatory cycles demonstrated by hormonal studies such as FSH/LH to the regularity of the ovary's physiological function (González et al., 2020). In total, these hormonal changes will increase reproductive health and reduce the signs of PCOS.

Figure 1: Hormonal Profile Changes after Nutraceutical Intervention

This figure compares the hormonal pattern of PCOS women before and after treatment using nutraceuticals. The results urge that interventions may reduce testosterone levels and raise the level of LH and FSH. Such changes may indicate the potential of Nutraceuticals like myo–inositol and D chiro inositol to bring about changes in Hormonal balance and, therefore, reproductive health outcomes (Merviel et al., 2021; Afiat et al., 2022).

Table 2: Efficacy of Nutraceuticals in Improving Hormonal Profiles

Nutraceutical	Effect on Hormonal Levels	Study Reference
Myo-inositol	Reduced total testosterone levels	Merviel et al., 2021
D-chiro-inositol	Improved ovulation rates	Afiat et al., 2022
Omega-3 Fatty Acids	Decreased inflammatory markers	Zhou et al., 2022
Vitamin D	Enhanced menstrual regularity	Kaur & Verma, 2023

In this tabular form, you notice which of the nutraceuticals have been most penetrative in addressing hormonal disruption in women with PCOS. For instance,D-chiro-inositoland Myo-inositol have been helpful when it

comes to reducing testosterone levels and encouraging ovulation. These omega-3 fatty acids boost reduced inflammation and are vital in hormone balance. In combination with PCOS, it appears that supplementation with vitamin D increases the regularity of menses (González et al., 2020; Alesi et al., 2022).

4.2 Metabolic Outcomes

Other than hormonal balance, other metabolic changes are expected to improve when taking nutraceutical foods. Moreover, it is better illustrated in enhancing insulin sensitivity and reducing insulin resistance in women with PCOS (Zhou et al., 2022). This research will point out that Myo-inositol supplementation reduces fasting insulin and metabolic markers such as BMI and waist size (Kaur & Verma, 2023).

For example, one research study (Merviel et al., 2021) tested the effect of Myo-inositol on distressed women who had improved their HOMA-IR significantly, which indicates better IR. Fasting glucose levels and lipid profiles are expected to decrease while total cholesterol and triglyceride levels decrease. For this reason, women suffering from PCOS are prone to metabolic syndrome and cardiovascular diseases (Gavali et al., 2021).

In addition, the addition of vitamins like Vitamin D and minerals like Zinc in tandem with Myo-inositol is also predicted to boost metabolic outcomes further. Vitamin D impairs insulin sensitivity and is involved in regulating menstrual cycles (Alesi et al., 2022). Therefore, the combined use of these nutraceuticals may produce overall metabolic benefits for women with PCOS.

Figure 2: Metabolic Parameter Improvements Post-Intervention

Illustrated in this figure are the changes in the metabolic parameters in women with PCOS on nutraceutical supplementation. Different studies show enhanced beneficial effects in insulin and significantly reduced fasting blood glucose and lipid profile (triglyceride and cholesterol) concentrations. It is also reassuring that these findings point to ways to enhance metabolic health and diminish liabilities associated with metabolic syndrome induced by PCOS and that nutraceuticals can achieve this.

Table 3: Impact of Nutraceuticals on Metabolic Parameters

Nutraceutical	Effect on Metabolic Markers	Study Reference
Myo-inositol	Improved HOMA-IR scores	Davinelli et al., 2020
Omega-3 Fatty Acids	Reduced triglycerides and cholesterol	Zhou et al., 2022
Zinc	Enhanced insulin sensitivity	Ghanei et al., 2018
Vitamin D	Lowered fasting glucose levels	Afiat et al., 2022

This table presents the effect of several nutraceuticals on these metabolic parameters when applied to treat PCOS. A statistically significant negative correlation exists between HOMA-IR and myo-inositol and between cholesterol and total omega-3 fatty acids. It was also mentioned that Zinc supplements could improve insulin sensitivity while Vitamin D can reduce fasting glucose levels. These findings indicate the potential for using nutraceuticals to overcome the metabolic dysfunctionality of PCOS (Kaur & Verma, 2023; González et al., 2020).

4.3 Fertility Enhancements

Infertilityertiyeptilly high among sufferers, and the e, expected impacts on fertility boosts are favourable. Interventions withD-chiro-inositoland Myo-inositol have established the prospect of enhancing the rates of

ovulation and reproductive function. Despite the existing clinical evidence of increased oocyte quality and numbers during ART procedures like IVF after Myo-inositol supplementation (Merviel et al. 2021; Xu et al. 2022).

For example, in a trial of women who were undergoing IVF, the chances of ovulation were much higher among the women who had taken Myo-inositol supplements than among those who had exercised standard treatment only (Davinelli et al., 2020). Also, reduced misalignment of periods is expected to benefit women who wish to conceive naturally, that is, without the use of assisted reproductive technologies.

Consequently, this study will be expected to generate positive results in fertility rates, an increased ability to ovulate regularly throughout the year, and a general enhancement of the fertility health of women of reproductive age. With these results, not only will knowledge about the efficacy of nutraceuticals be presented, but such knowledge will also be communicated to clinical practice, which can sufficiently address PCOS.

Figure 3: Expected Fertility Outcomes After Nutraceutical Treatment

Last of all, this figure illustrates the fertility outcome expected if women with PCOS opt for nutraceutical treatment. D-chiro-inositol andMyo-inositol improve female fertility and increase ovulation frequency, and the menstrual cycle is also expected. In addition, increased oocyte quality is helpful for women treating assisted reproductive technology (Merviel et al., 2021; Xu et al., 2022). Based on these results, it is justifiable to include nutraceuticals within fertility management plans for women with PCOS.

Table 4: Expected Improvements in Fertility Outcomes

Outcome	Expected Improvement	Study Reference
Ovulation Rates	Increased by up to 70%	Merviel et al., 2021
Menstrual Regularity	Improved in over 60% of participants	Ibrahim et al., 2020
Oocyte Quality	Enhanced quality reported	Xu et al., 2022

In this table, based on the previously described alterations in the pathways affected by the nutraceutical interventions for women with PCOS, we present anticipated shifts in fertility outcomes. 57 This observation of decreasing COCs on days 2-4 post-treatment explains the expected increase in ovulation of approximately 70 % owing to D chiro inositol andmyo inositol combinations. In addition, these nutraceuticals enhance the menstrual cycle and oocyte competence, further supporting the possibility of these nutraceuticals to prevent a negative impact on reproductive health (Alesi et al., 2022; Merviel et al., 2021).

5. Discussion

5.1 Interpretation of Expected Findings

The potential consequences of the expected outcomes of this study for present management approaches to Polycystic Ovary condition (PCOS) are explained. It is, therefore, clear that since PCOS is a complex condition, its treatments must also be complex, including all aspects of hormones and metabolic abnormalities. Adjuvant use of nutraceuticals, including myo-inositol, D-chiro-inositol, Omega 3 fatty acids, vitamins, and minerals, can enhance the effectiveness of the present management strategies with minimal adverse effects compared to pharmacological therapies.

For instance, as other studies have suggested, Myo-inositol and D-chiro-inositol effectively improve hormonal

disturbances on the path to anticipated hormonal changes, including reduced testosterone levels and enhanced o. These data suggest that nutraceuticals could potentially complement regular medications like metformin and hormone-containing contraceptives. To continue, metformin works on insulin resistance, whereas adding myo-inositol might have an added value due to its ability to address hyperandrogenism and ovulation (Akhtar et al., 2021). In this integrative way, this approach increases the management of PCOS and aligns with patient autonomy for less invasive treatment options.

Additionally, the anticipated metabolic outcome improvements are particularly applicable because PCOS is extremely common in women with metabolic syndrome. Lifestyle modifications and nutraceutical supplementation produce significant falls in insulin resistance and improvement in lipid profiles (Zhou et al., 2022). The finding supports the potential that nutraceuticals can serve as second-line Therapies (after modifying lifestyle interventions such as diet and exercise) for PCOS. Together, these interventions might also lower the risks of PCOS later in life, including cardiovascular diseases and type 2 diabetes (González et al., 2020).

A crucial implication of the work detailed in this study is the expected enhancements in fertility outcomes. One common problem associated with PCOS in women is the problems around infertility because they have issues regarding ovulation and hormonal imbalance. Results suggest that combining Myo-inositol and D-chiro-inositol has improved both ovulatory rates and overall reproductive health (Merviel et al., 2021; Xu et al., 2022). Consequently, these nutraceuticals could serve as promising substitutes or adjuvant to conventional fertility treatments, especially for women desiring conception without the use of more invasive techniques, such as in vitro fertilization (IVF).

In addition, the expanding database supporting nutraceuticals in managing PCOS symptoms marks the trend toward personalized medicine. Following this, more patients are looking for complementary therapies to manage their conditions, and healthcare providers need to be ready to offer recommended choices, including complementary therapies, as part of the holistic treatment plan (Scannell et al., 2023). The approach also empowers patients by making them part of the healthcare process and helping them build a partnership with their healthcare provider.

Nevertheless, it should be emphasized that although the results are promising, nutraceutical use in clinical practice still needs to be established using standardized protocols. Studies are characterized by a variability in dosages, interventions, and treatment duration (Alesi et al., 2022; Genazzani et al., 2020). Optimal dosing regimens for nutraceutical supplementation and the long-term effects of nutraceutical supplementation on PCOS management should be defined for future clinical trials.

5.2 Limitations of Existing Research

More recently, there has been a focus on the possibility of using nutraceuticals as part of the approach to the treatment of PCOS. However, the existing literature needs to be revised. The most pressing issue is the heterogeneity of the study designs, which stands in the way of a definitive conclusion about the efficacy of different nutraceuticals. Weight loss drug Signifor LAR does not protect against future diabetes and cardiovascular disease. Impact of obesity on treatment options for type II diabetes. J Diabetes Metab Disord. Variability can result in inconsistent results and, therefore, a lack of standardization of protocols for the clinical use of nutraceuticals in clinical practice.

Further, some studies have reported beneficial effects with nutraceuticals, such as D chiro inositol andmyo inositol. However, the evidence is frequently from tiny sample sizes or short intervention periods. For example,

many trials test the efficacy of a nutraceutical alone without appreciating it when paired with other supplements, conventional treatments, or in combination with each other. However, the lack of exhaustive analysis may limit our ability to fully appreciate the dynamics with which these compounds are brought into play by complex biological systems surrounding PCOS.

Further, more extended investigations are required to explore the durability of an advantage from the additional consumption of nutraceuticals. Many of these positive changes, such as hormonal profiles or metabolic parameters, have been identified during short-term interventions. However, the impact on reproductive health and well-being, with the long-term follow-up wanted to assess the safety of interventions, remains an area for further research. Protracted nutraceutical administration and utilization have not been sufficiently established to make any convincing argument, which is even more dubious in some patients who may suffer from side effects or become tolerant to the pill's effects.

Another major weakness is that the results, including the number of menstrual cycles over a calendar period and the intensity of symptoms, are based on the data collected from the participants. Subjective measures can generate bias and variability that do not accurately reflect actual changes in clinical status. Hormonal assays and metabolic evaluations are necessary to aid in determining if treatment is objective.

Finally, despite the prevalence of safe alternatives to pharmaceutical compounds, nutraceuticals are also needed for the rigorous evaluation of safety. A crucial deficiency in the current literature is complete reporting on adverse effects caused by taking nutraceutical supplementation, limiting clinicians' choices of treatment options.

5.3 Future Research Directions

With these limitations, several areas of future research need to be prioritized to better understand how nutraceuticals are used in the management of PCOS. First, specific combinations' efficacy and nutraceuticals need to be further studied using large-scale clinical trials on different populations. Moreover, to assess a particular treatment's effects on different demographies, these trials should be conducted across various ages and body mass index (BMI).

Further investigations will be required to understand the appropriate doses and the treatment regimen of various kinds of nutraceuticals. If standardized protocols can be developed, the intercomparisons will be more accessible, and the results will be even more accurate (Alesi et al., 2022). Other combinations could also be examined to gather further information on how these nutraceuticals work on the hormonal balance and metabolic profile.

In this way, future histological and clinical long-term randomized controlled trials comparing the effects of continued assortative nutraceutical supplement usage in women with PCOS can be better evaluated. Studying like this could reveal how often patients covenanted and how such treatments related to the usual treatments.

Further research on the molecular level through which these nutraceuticals impact PCOS would be a great stride toward the therapeutic exploitation of the discoveries. For instance, it is possible to define new intervention targets depending on the influence of specific bioactive compounds on insulin signalling pathways and functions of the ovaries.

Finally, the promise of safety in supplement form must be moderated through a detailed analysis of the risks associated with nutraceutical supplementation. Others are extensive reporting on side effects to benefit clinical decision-making and to bolster patients' confidence in other therapies they consider experimental.

6. Conclusion

This study's contribution has pointed out the therapeutic potential of nutraceuticals in combating Polycystic Ovary Syndrome, a common endocrine disorder in females of reproductive age. Researchers will likely find that nutraceuticals, such aschiro-inositol, D—myoinositol, omega-3 fatty acids, and other vitamins and minerals, can improve hormonal profiles, enhance metabolic health, and increase reproductive function. These findings align with other writing that supports using nutraceuticals as complementary therapies alongside conventional treatments.

The need for evidence-based nutraceuticals to be integrated into clinical practice must be over-emphasized. There is an excellent interest in nutraceuticals as they might improve the action outcome of women with PCOS since the latter resorts to alternative pharmacological treatments mainly out of concerns about adverse effects and long-term efficacy. The supplements that address both hormonal imbalances and metabolic dysfunctions are an overall approach to simply managing PCOS symptoms and are much more likely to help improve PCOS patients' quality of life.

Additionally, the results presented from this study reinforce that healthcare providers should follow the frontier research of nutraceuticals. Given that the FDA approves no efficacious treatments for the main symptoms of PCOS and that studies have demonstrated the differential effectiveness of these alternatives, clinicians should discuss these alternatives with patients when constructing individualized management plans for PCOS. This patient-centered approach gives women the power to be active partners in healthcare and facilitates a partnership between patients and healthcare professionals.

Finally, as more and more evidence of the efficacy of nutraceuticals in PCOS management accumulates, future research should fill in these knowledge gaps using group studies aiming at standardizing protocol. The therapeutic benefits of these interventions will be crucially validated, and their safe integration into routine clinical practice will be ensured with this ongoing investigation. The call to action for clinicians is clear: We embrace the potential of nutraceuticals as a part of a more comprehensive strategy for managing PCOS related to patient care and outcomes in this complex disorder.

Reference

[1] Abbasi, S. (2019). Efficacy Studies of Fenugreek Seeds against Polycystic Ovarian Syndrome. *Texila International Journal of Public Health*, 7, 181-188. https://doi.org/10.21522/tijph.2013.07.04.art020.

[2] Abhari, S., Khanbabaei, R., Roodbari, N., Parivar, K., & Yaghmaei, P. (2020). Curcumin-loaded super-paramagnetic iron oxide nanoparticle affects apoptotic factors expression and histological changes in a prepubertal mouse model of polycystic ovary syndrome-induced by dehydroepiandrosterone - A molecular and stereological study.. *Life sciences*, 117515. https://doi.org/10.1016/j.lfs.2020.117515.

[3] Afiat, M., Lor, A., Najafi, M., Ghazanfarpour, M., & Jafarabadi, M. (2022). Examining the Effect of Chamomile on Clinical Symptoms and Hormonal Parameters Among Patients With Polycystic Ovarian Syndrome. *Journal of Family & Reproductive Health*, 16, 248 - 253. https://doi.org/10.18502/jfrh.v16i4.11355.

[4] Ajibare, A., Akintoye, O., Famurewa, A., Folawiyo, M., Bamisi, O., Asuku, A., Oyegbola, O., Akintayo, C., Olofinbiyi, B., & Omotuyi, O. (2023). Synergistic Action of Virgin Coconut Oil and

Clomiphene in Reversing Endocrine Dysregulation in Letrozole-Model of Polycystic Ovarian Syndrome in Rats: Role of Nrf2/HMOX-1 Pathway.. *Journal of medicinal food*, 26 9, 683-691. https://doi.org/10.1089/jmf.2023.0023.

[5] Akhtar, N., Banu, H., Morshed, M., Sultana, T., Begum, A., & Hasanat, M. (2021). Effects of metformin on polycystic ovary syndrome: a randomized, double-blind, placebo-controlled study. *IMC Journal of Medical Science*. https://doi.org/10.3329/imcjms.v15i2.55808.

[6] Alesi S, Ee C, Moran LJ, Rao V, Mousa A. Nutritional Supplements and Complementary Therapies in Polycystic Ovary Syndrome. Advances in Nutrition. 2022 Jul;13(4):1243–66.

[7] Asad, M., Banerjee, M., Nandy, M., Naskar, T., & Kayal, A. (2019). The effect of standard treatment modalities on clinical and ovarian parameters in polycystic ovarian syndrome. *International Journal of Clinical Obstetrics and Gynaecology*. https://doi.org/10.33545/gynae.2019.v3.i5d.353.

[8] Atwa, K., Farrag, M., El-Sayed, M., Taha, O., & Elprince, M. (2020). Evaluation of the effect of trans-vaginal ovarian needle punctures on women with polycystic ovary syndrome.. *Journal of gynecology obstetrics and human reproduction*, 101937. https://doi.org/10.1016/j.jogoh.2020.101937.

[9] Aversa, A., Vignera, S., Rago, R., Gambineri, A., Nappi, R., Calogero, A., & Ferlin, A. (2020). Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions. *Frontiers in Endocrinology*, 11. https://doi.org/10.3389/fendo.2020.00516.

[10] Bahman, A., Abotorabi, S., Ghale, T., & Javadi, A. (2018). Comparing effect administration calcium-vitamin D and metformin in regulating menstrual cycle in women with polycystic ovarian syndrome. *The Journal of Qazvin University of Medical Sciences*, 22, 4-12. https://doi.org/10.29252/QUMS.22.1.12.

[11] Bizzarri, M., & Monti, N. (2019). Reproducibility crisis. Impact on the uncontrolled release of nutraceutical preparations., 3, 9-10. https://doi.org/10.13133/2532-5876_5.2.

[12] Chopra, K. (2018). What to Do: Infertility in Polycystic Ovarian Syndrome. *Perceptions in Reproductive Medicine*. https://doi.org/10.31031/PRM.2018.02.000536.

[13] Chudzicka-Strugała, I., Kubiak, A., Banaszewska, B., Zwoździak, B., Siakowska, M., Pawelczyk, L., & Duleba, A. (2021). Effects of synbiotic supplementation and lifestyle modifications on women with polycystic ovary syndrome. *The Journal of clinical endocrinology and metabolism*. https://doi.org/10.1210/clinem/dgab369.

[14] Cocetta, V., Tinazzi, M., Giacomini, I., Rosato, B., Ragazzi, E., Berretta, M., & Montopoli, M. (2022). Clinical Evidence of Interaction Between Nutraceutical Supplementation and Platinum-based Chemotherapy.. *Current medicinal chemistry*. https://doi.org/10.2174/0929867329666220527120237.

[15] Corrie, L., Gulati, M., Vishwas, S., Kapoor, B., Singh, S., Awasthi, A., & Khursheed, R. (2021). Combination therapy of curcumin and fecal microbiota transplant: Potential treatment of polycystic ovarian syndrome.. *Medical hypotheses*, 154, 110644. https://doi.org/10.1016/j.mehy.2021.110644.

[16] Corte, L., Foreste, V., Barra, F., Gustavino, C., Alessandri, F., Centurioni, M., Ferrero, S., Bifulco, G., & Giampaolino, P. (2020). Current and experimental drug therapy for the treatment of polycystic ovarian syndrome. *Expert Opinion on Investigational Drugs*, 29, 819 - 830. https://doi.org/10.1080/13543784.2020.1781815.

[17] Cui, D., Xu, Z., Qiu, S., & Sun, Y. (2022). Nasturtium officinale L. and metformin alleviate the estradiol -induced polycystic ovary syndrome with synergistic effects through modulation of Bax/Bcl-2/p53/caspase-3 signaling pathway and anti-inflammatory and anti-oxidative effects.. *Journal of food biochemistry*, e14462. https://doi.org/10.1111/jfbc.14462.

[18] Davinelli, S., Nicolosi, D., Cesare, C., Scapagnini, G., & Marco, R. (2020). Targeting Metabolic Consequences of Insulin Resistance in Polycystic Ovary Syndrome by D-chiro-inositol and Emerging Nutraceuticals: A Focused Review. *Journal of Clinical Medicine*, 9. https://doi.org/10.3390/jcm9040987.

[19] El-Garhi, I., El-Omda, F., El-Khatib, G., & Awad, A. (2019). Effect of Metformin Only versus Effect of Metformin and Corticosteroids after Laparoscopic Ovarian Drilling on Ovulation in Women with Clomiphene Citrate Resistant Polycystic Ovary Syndrome. *The Egyptian Journal of Hospital Medicine*. https://doi.org/10.12816/EJHM.2019.22433.

[20] Emam, S., Abd-Elsalam, R., Azouz, A., Ali, S., Badawy, S., Ibrahim, M., Hassan, B., Issa, M., & Elmosalamy, S. (2021). Linum usitatissimum seeds oil down-regulates mRNA expression for the steroidogenic acute regulatory protein and Cyp11A1 genes, ameliorating letrezole-induced polycystic ovarian syndrome in a rat model.. *Journal of Physiology and pharmacology: an official journal of the Polish Physiological Society*, 72 1. https://doi.org/10.26402/jpp.2021.1.06.

[21] Espinoza, J., Alvarado, W., Venegas, B., Domínguez, R., & Morales-Ledesma, L. (2018). Pharmacological sympathetic denervation prevents the development of polycystic ovarian syndrome in rats injected with estradiol valerate. *Reproductive Biology and Endocrinology: RB&E*, 16. https://doi.org/10.1186/s12958-018-0400-8.

[22] Frank, C., & Wim, D. (2021). Nutraceutical Treatment of Patients with Polycystic Ovary Syndrome. *Open Journal of Obstetrics and Gynecology*. https://doi.org/10.4236/ojog.2021.119105.

Frank, C. and Wim, D. (2021) Nutraceutical Treatment of Patients with Polycystic Ovary Syndrome. *Open Journal of Obstetrics and Gynecology*, 11, 1117-1124. doi: 10.4236/ojog.2021.119105.

[23] Gadani, M., Upadhyay, R., Raut, S., & Badak, S. (2023). In vitro anti-estrogenic potential of FertiZen-R™- a nutraceutical ingredient for estrogen modulation. *International Journal of Reproduction, Contraception, Obstetrics and Gynecology*. https://doi.org/10.18203/2320-1770.ijrcog20230524.

[24] Gao, Z., Wang, G., Ma, X., Tan, H., Zhang, C., Yin, X., Suo, F., Yao, R., & Yan, X. (2022). Troxerutin attenuates insulin resistance via pancreatic IL-22/JAK1/STAT3 signaling activation in dihydrotestosterone-induced PCOS rats.. *American journal of physiology. Endocrinology and metabolism*.

https://doi.org/10.1152/ajpendo.00150.2022.

[25] Gavali, U., Pawar, M., Aher, G., & Shinde, S. (2021). Clinical Profile of Polycystic Ovarian Syndrome Patients In Tertiary Care Hospital. *VIMS Health Science Journal*. https://doi.org/10.46858/vimshsj.8303.

[26] Genazzani AD, Prati A, Genazzani AR, Battipaglia C, Simoncini T, Szeliga A, et al. Synergistic effects of the integrative administration of acetyl-L-carnitine, L-carnitine, L-arginine, and N-acetyl-cysteine on metabolic dynamics and on hepatic insulin extraction in overweight/obese patients with PCOS.

[27] Ghanei, N., Rezaei, N., Amiri, G., Zayeri, F., Makki, G., & Nasseri, E. (2018). The probiotic supplementation reduced inflammation in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial. *Journal of Functional Foods*, 42, 306-311. https://doi.org/10.1016/J.JFF.2017.12.047.

[28] Giri, A., Joshi, A., Shrestha, S., & Chaudhary, A. (2022). Metabolic Syndrome among Patients with Polycystic Ovarian Syndrome Presenting to a Tertiary Care Hospital: A Descriptive Cross-Sectional Study. *JNMA: Journal of the Nepal Medical Association*, 60, 137 - 141. https://doi.org/10.31729/jnma.7221.

[29] González, F., Mather, K., Considine, R., Abdelhadi, O., & Acton, A. (2020). Salicylate administration suppresses the inflammatory response to nutrients and improves ovarian function in polycystic ovary syndrome.. *American journal of physiology. Endocrinology and metabolism*. https://doi.org/10.1152/ajpendo.00228.2020.

[30] Ibrahim, Y., Toni, N., Thabet, K., Hegazy, A., & Bahaa, H. (2020). Ameliorating effect of tocilizumab in letrozole-induced polycystic ovarian syndrome in rats via improving insulin resistance and down-regulation of VEGF/ANGPT/PDGF. *Minia Journal of Medical Research*. https://doi.org/10.21608/mjmr.2022.221583.

[31] Jamilian, M., Foroozanfard, F., Mirhosseini, N., Kavossian, E., Aghadavod, E., Bahmani, F., Ostadmohammadi, V., Kia, M., Eftekhar, T., Ayati, E., Mahdavi-nia, M., & Asemi, Z. (2019). Effects of Melatonin Supplementation on Hormonal, Inflammatory, Genetic, and Oxidative Stress Parameters in Women With Polycystic Ovary Syndrome. *Frontiers in Endocrinology*, 10. https://doi.org/10.3389/fendo.2019.00273.

[32] Kaur H, Verma DSK. NUTRITIONAL STRATEGIES FOR ALLEVIATING SYMPTOMS OF POLYCYSTIC OVARIAN SYNDROME: A REVIEW OF CLINICAL EVIDENCE. 2023;30(19).

[33] Kelany, O., khouly, N., Hamza, H., & Gafar, H. (2020). Effects of cabergoline administration on uterine perfusion in women with polycystic ovarian syndrome. *Menoufia Medical Journal*, 33, 492 - 496. https://doi.org/10.4103/mmj.mmj_299_19.

[34] Khajouei, A., Hosseini, E., Abdizadeh, T., Kian, M., & Ghasemi, S. (2021). Beneficial effects of minocycline on the ovary of polycystic ovary syndrome mouse model: Molecular docking analysis and evaluation of TNF-α, TNFR2, TLR-4 gene expression.. *Journal of Reproductive Immunology*, 144, 103289. https://doi.org/10.1016/j.jri.2021.103289.

[35] Kiani AK, Donato K, Dhuli K, Stuppia L, Bertelli M. Dietary supplements for polycystic ovary syndrome. Journal of Preventive Medicine and Hygiene. 2022 Oct 17; Vol. 63 No. 2S3:E206 Pages.

[36] Kłosińska, M., & Kaczyńska, A. (2021). Polycystic ovarian syndrome - management and treatment. *Journal of Education, Health and Sport*. https://doi.org/10.12775/35170.

[37] Leena, M., Silvia, G., Kannadasan, V., Jeyan, M., & Anandharamakrishnan, C. (2020). Synergistic potential of nutraceuticals: mechanisms and prospects for futuristic medicine.. *Food & function*, 11 11, 9317-9337. https://doi.org/10.1039/d0fo02041a.

[38] Li, Y., Tan, J., Wang, Q., Duan, C., Hu, Y., & Huang, W. (2019). Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial.. *Fertility and sterility*. https://doi.org/10.1016/j.fertnstert.2019.09.011.

[39] Malvasi, A., Tinelli, A., Lupica, G., Vimercati, A., Spyropoulou, K., Dellino, M., & Mynbaev, O. (2022). Effects of a combination of resveratrol and alpha-lipoic acid on body weight and adipose composition in women with PCOS: a preliminary pilot study.. *European review for medical and pharmacological sciences*, 26 18, 6578-6582. https://doi.org/10.26355/eurrev_202209_29757.

[40] Menichini, D., Ughetti, C., Monari, F., Vinci, P., Neri, I., & Facchinetti, F. (2022). Nutraceuticals and polycystic ovary syndrome: a systematic review of the literature. *Gynecological Endocrinology*, 38, 623 - 631. https://doi.org/10.1080/09513590.2022.2089106.

[41] Merviel, P., James, P., Bouée, S., Guillou, M., Rince, C., Nachtergaele, C., & Kerlan, V. (2021). Impact of Myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies. *Reproductive Health*, 18. https://doi.org/10.1186/s12978-021-01073-3.

[42] Mondal, S., & Sarkar, P. (2021). Effect of metformin in treating polycystic ovarian syndrome among women attending a tertiary care setting -A prospective observational study. *Indian Journal of Obstetrics and Gynecology Research*. https://doi.org/10.18231/J.IJOGR.2021.040.

[43] Naseri, L., Khazaei, M., & Khazaei, M. (2021). Synergic effect of bee pollen and metformin on proliferation and apoptosis of granulosa cells: A rat model of polycystic ovary syndrome.. *Journal of food biochemistry*, e13635. https://doi.org/10.1111/jfbc.13635.

[44] Nazirudeen, R., Natarajan, V., Jayaraman, S., & Subbiah, S. (2022). Abstract 30: A randomized control trial comparing myoinositol-based therapy in combination with metformin versus metformin monotherapy on the clinical and hormonal parameters in obese reproductive-age women with polycystic ovarian syndrome. *Indian Journal of Endocrinology and Metabolism*, 26, S16 - S16. https://doi.org/10.4103/2230-8210.342144.

[45] Ostadmohammadi, V., Jamilian, M., Bahmani, F., & Asemi, Z. (2019). Vitamin D and probiotic co-supplementation affect mental health, hormonal, inflammatory, and oxidative stress parameters in

women with polycystic ovary syndrome. *Journal of Ovarian Research*, 12. https://doi.org/10.1186/s13048-019-0480-x.

[46] Parker, M., Warren, A., Nair, S., & Barnard, M. (2020). Adherence to treatment for polycystic ovarian syndrome: A systematic review. *PLoS ONE*, 15. https://doi.org/10.1371/journal.pone.0228586.

[47] Peng, F., Hu, Y., Peng, S., Zeng, N., & Shi, L. (2022). Apigenin exerts protective effect and restores ovarian function in dehydroepiandrosterone induced polycystic ovary syndrome rats: a biochemical and histological analysis. *Annals of Medicine*, 54, 578 - 587. https://doi.org/10.1080/07853890.2022.2034933.

[48] Pierro, F., Sultana, R., Eusaph, A., Abrar, S., Bugti, M., Afridi, F., Farooq, U., Iqtadar, S., Ghauri, F., Makhduma, S., Nourin, S., Kanwal, A., Bano, A., Bugti, A., Mureed, S., Ghazal, A., Irshad, R., Recchia, M., Bertuccioli, A., Putignano, P., Riva, A., Guasti, L., Zerbinati, N., & Khan, A. (2023). Effect of Berberine Phytosome on reproductive, dermatologic, and metabolic characteristics in women with polycystic ovary syndrome: a controlled, randomized, multi-centric, open-label clinical trial. *Frontiers in Pharmacology*, 14. https://doi.org/10.3389/fphar.2023.1269605.

[49] Ragy, M., Abdel-Hamid, H., & Toni, N. (2018). Pathophysiological changes in experimental polycystic ovary syndrome in female albino rats: Using either hemin or L-arginine. *Journal of Cellular Physiology*, 234, 8426 - 8435. https://doi.org/10.1002/jcp.27757.

[50] Ranjbary, A., Mehrzad, J., Garoussi, M., & Zohdi, J. (2022). Long-Term Oral Administration of Oregano Essence Effectively Relieves Polycystic Ovarian Rats through Endocrine and Inflammatory Balance. *Evidence-based Complementary and Alternative Medicine: eCAM*, 2022. https://doi.org/10.1155/2022/5303583.

[51] Raoofi, A., Rezaie, M., Delbari, A., Ghoreishi, S., Sichani, P., Maleki, S., Nasiry, D., Akhlaghi, M., Ebrahimi, V., & Khaneghah, A. (2022). Therapeutic potentials of the caffeine in polycystic ovary syndrome in a rat model: Via modulation of proinflammatory cytokines and antioxidant activity. *Allergologia et immunopathologia*, 50 6, 137-146 . https://doi.org/10.15586/aei.v50i6.715.

[52] Rezaei, M., Zandokili, F., Zare, S., Daneshi, E., & Rahimi, K. (2021). Histomorphometric Changes of Ovary in Polycystic Ovary Syndrome in Rats after Administration of Evening Primrose Oil. *Armaghane Danesh*. https://doi.org/10.52547/armaghanj.26.2.139.

[53] Rocha, A., Oliveira, F., Azevedo, R., Silva, V., Peres, T., Cândido, A., Gomes, K., & Reis, F. (2019). Recent advances in the understanding and management of polycystic ovary syndrome. *F1000Research*, 8. https://doi.org/10.12688/f1000research.15318.1.

[54] Romualdi, D., Versace, V., & Lanzone, A. (2020). What is new in the landscape of insulin-sensitizing agents for polycystic ovary syndrome treatment. *Therapeutic Advances in Reproductive Health*, 14. https://doi.org/10.1177/2633494120908709.

[55] Sadeghi, H., Adeli, I., Calina, D., Docea, A., Mousavi, T., Daniali, M., Nikfar, S., Tsatsakis, A., & Abdollahi, M. (2022). Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing. *International Journal of Molecular Sciences*, 23. https://doi.org/10.3390/ijms23020583.

[56] Scannell, N., Mantzioris, E., Rao, V., Pandey, C., Ee, C., Mousa, A., Moran, L., & Villani, A. (2023). Type and Frequency in Use of Nutraceutical and Micronutrient Supplementation for the Management of Polycystic Ovary Syndrome: A Systematic Scoping Review. *Biomedicines*, 11. https://doi.org/10.3390/biomedicines11123349.

[57] Sen, S. (2023). A comparative study of different treatment modalities of polycystic ovarian syndrome in women of reproductive age group at tertiary care centre. *International Journal of Reproduction, Contraception, Obstetrics and Gynecology*. https://doi.org/10.18203/2320-1770.ijrcog20232739.

[58] Shamasbi, S., Ghanbari-Homayi, S., & Mirghafourvand, M. (2019). The effect of probiotics, prebiotics, and synbiotics on hormonal and inflammatory indices in women with polycystic ovary syndrome: a systematic review and meta-analysis. *European Journal of Nutrition*, 59, 433-450. https://doi.org/10.1007/s00394-019-02033-1.

[59] Shikh, E., Makhova, A., Grebenshchikova, L., & Bagdasaryan, A. (2022). Micronutrient support among women of reproductive age with polycystic ovary syndrome complicated by metabolic risks. *Voprosy ginekologii, akušerstva i perinatologii*. https://doi.org/10.20953/1726-1678-2022-1-108-115.

[60] Thakur, D., Singh, D., Tripathi, D., & LuFang, D. (2021). Effect of yoga on polycystic ovarian syndrome: A systematic review.. *Journal of bodywork and movement therapies*, 27, 281-286. https://doi.org/10.1016/J.JBMT.2021.02.018.

[61] Vaidya, A., Yadav, S., & Vaidya, A. (2020). A Study on the Clinical and Hormonal Profile of Polycystic Ovarian Syndrome Patients Attending a Tertiary Care Hospital: A Descriptive Cross-sectional Study. *JNMA: Journal of the Nepal Medical Association*, 58, 875 - 878. https://doi.org/10.31729/jnma.5694.

[62] Vitale, S., Palumbo, M., Conde-López, C., Mendoza, N., Mendoza-Tesarik, R., & Tesarik, J. (2020). Effect of growth hormone administration on ICSI outcomes in patients with polycystic ovary syndrome and recurrent implantation failure: A retrospective cross-over study. *International Journal of Gynecology & Obstetrics*, 153. https://doi.org/10.1002/ijgo.13547.

[63] Xu, B., Dai, W., Liu, L., Han, H., Zhang, J., Du, X., Pei, X., & Fu, X. (2022). Metformin ameliorates polycystic ovary syndrome in a rat model by decreasing excessive autophagy in ovarian granulosa cells via the PI3K/AKT/mTOR pathway.. *Endocrine journal*. https://doi.org/10.1507/endocrj.ej21-0480.

[64] Yang, L., Liang, F., Yuan, Y., Luo, X., Wang, Q., Yao, L., & Zhang, X. (2023). Efficacy of progestin-primed ovarian stimulation in women with polycystic ovary syndrome undergoing in vitro fertilization: a systematic review and meta-analysis. *Frontiers in Endocrinology*, 14. https://doi.org/10.3389/fendo.2023.1224858.

[65] Yang, H., Lee, S., Jo, S., Kim, A., Kim, E., Qu, F., Hong, E., & Lee, H. (2022). The Improvement Effect of D-Chiro-Inositol and Ecklonia cava K. in the Rat Model of Polycystic Ovarian Syndrome. *Frontiers in Pharmacology*, 13. https://doi.org/10.3389/fphar.2022.905191.

[66] Zhou, Y., Lan, H., Dong, Z., Li, W., Qian, B., Zeng, Z., He, W., & Song, J. (2022). Rhamnocitrin Attenuates Ovarian Fibrosis in Rats with Letrozole-Induced Experimental Polycystic

Ovary Syndrome. *Oxidative Medicine and Cellular Longevity*, 2022. https://doi.org/10.1155/2022/5558599.

[67] Zhao, J., Yang, Q., & Zhu, W. (2019). Drug use in patients with polycystic ovary syndrome at some hospitals. , 25, 1064-1067. https://doi.org/10.3760/CMA.J.ISSN.1007-1245.2019.07.017.

[68] Zhu, X., & Fu, Y. (2019). Randomized, Controlled Pilot Study of Low-Dose Human Chorionic Gonadotropin Administration Beginning From the Early Follicular Phase for Women With Polycystic Ovarian Syndrome Undergoing Ovarian Stimulation Using the Progesterone Protocol. *Frontiers in Endocrinology*, 10. https://doi.org/10.3389/fendo.2019.00875.

PMCID: PMC11130807.